<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul F Dellaripa, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonye K Danoff, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ira N Targoff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermatomyositis (DM) and polymyositis (PM) are classified as idiopathic inflammatory myopathies. Among patients with DM or PM, interstitial lung disease (ILD) is a major cause of morbidity and mortality. A general approach to the evaluation of ILD is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
         In patients with DM or PM, ILD must be distinguished from other causes of pulmonary disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-induced pneumonitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumomediastinum
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory muscle weakness
        </p>
        <p>
        </p>
        <p>
         The clinical manifestations and evaluation of ILD associated with DM and PM will be reviewed here. The treatment of respiratory diseases in DM and PM and the clinical manifestations and diagnosis of myositis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4357.html" rel="external">
          "Interstitial lung disease in dermatomyositis and polymyositis: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6419.html" rel="external">
          "Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of interstitial lung disease (ILD) varies widely (from 20 to 80 percent) among case series of patients with polymyositis (PM) and dermatomyositis (DM) [
         <a href="#rid1">
          1-4
         </a>
         ]. This variability is related to several factors, including the methods used to identify ILD (eg, lower rates if high-resolution computed tomography [HRCT] is not used), the proportions of the different subsets of myositis (eg, amyopathic DM, presence of antisynthetase antibodies, presence of melanoma differentiation-associated gene 5 [MDA-5] antibodies), and the presence of an underlying malignancy [
         <a href="#rid1">
          1-3,5-12
         </a>
         ].
        </p>
        <p>
         Certain subsets of DM and PM appear to be associated with different frequencies of ILD. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 62 patients with inflammatory myopathies, ILD was diagnosed in approximately half of patients with PM or DM, and almost all of patients with clinically amyopathic dermatomyositis [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another retrospective series of 90 patients with DM or PM and serum anti-Jo-1 antibodies (an antisynthetase antibody), ILD was identified in 86 percent [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Laboratory testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ILD is less common in patients with inflammatory myositis associated with malignancy [
         <a href="#rid11">
          11,14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">
          "Malignancy in dermatomyositis and polymyositis", section on 'Clinical risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         One study evaluating over 1200 patients with inflammatory myopathies found an association between HLA alleles belonging to ancestral haplotype 8.1 (
         <em>
          HLA B*08, HLA C*07, HLA DRB1*03
         </em>
         ) and the development of ILD [
         <a href="#rid16">
          16
         </a>
         ]. Ancestral haplotype 8.1 is present in approximately 6 percent of the European population, but it can also be found in 1 percent of Black or Hispanic Americans. The ILD association is mediated primarily by the propensity for individuals with this haplotype to develop anti-Jo-1 antibodies [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathologic appearance of ILD in DM and PM reflects the patterns of lung pathology associated with the idiopathic interstitial pneumonias  (
         <a class="graphic graphic_table graphicRef95445" href="/z/d/graphic/95445.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p>
         The histologic patterns of ILD that have been observed in biopsy and autopsy studies of patients with PM and DM include [
         <a href="#rid15">
          15,18,19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonspecific interstitial pneumonia (NSIP) (see
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia", section on 'Histopathology and interpretation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Usual interstitial pneumonia (UIP) (see
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Usual interstitial pneumonia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organizing pneumonia (OP), previously known as bronchiolitis obliterans with organizing pneumonia (BOOP) (see
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Histopathologic diagnosis of organizing pneumonia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse alveolar damage (DAD), seen in patients with acute interstitial pneumonia (AIP) (see
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)", section on 'Pathology'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         These patterns are indistinguishable histopathologically from the idiopathic interstitial pneumonias and the forms of ILD that occur in other systemic rheumatic diseases such as systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis. Details related to the specific histopathologic features of these subtypes of ILD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p>
         Lung biopsy is typically not necessary for the diagnosis or management of ILD in PM/DM, thus data are limited on histopathologic patterns. NSIP is the most common histopathologic pattern of ILD in small series of patients with DM and PM [
         <a href="#rid15">
          15,19-21
         </a>
         ]. The relative frequency of the different histopathologic patterns was evaluated in a series of 22 patients with DM or PM who underwent lung biopsy [
         <a href="#rid15">
          15
         </a>
         ]. NSIP was by far the most common finding (18 patients), followed by DAD (two patients), UIP (one patient), and OP (one patient). In a separate series of patients with anti-aminoacyl-tRNA synthetase antibodies (anti-Jo-1) who underwent lung biopsy, four had NSIP and four had OP [
         <a href="#rid21">
          21
         </a>
         ]. Additionally, NSIP and OP can be present concomitantly [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with interstitial lung disease (ILD) typically complain of dyspnea and a nonproductive cough, although some patients are asymptomatic and ILD is suspected because of an abnormal lung exam or an abnormal chest radiograph [
         <a href="#rid24">
          24,25
         </a>
         ]. Occasionally, dermatomyositis (DM) or polymyositis (PM)-related ILD presents with rapid onset and progression, particularly in patients with amyopathic dermatomyositis [
         <a href="#rid26">
          26
         </a>
         ]. The respiratory manifestations of ILD in patients with DM or PM parallel those described for patients with the idiopathic interstitial pneumonias, although the muscle weakness associated with these myopathies may influence the degree of dyspnea and risk of aspiration. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="local">
          'Respiratory muscle weakness'
         </a>
         below.)
        </p>
        <p>
         The temporal relationship between the onset of ILD and myositis is variable [
         <a href="#rid27">
          27
         </a>
         ]. ILD can precede the diagnosis of overt myositis by months or years, appear simultaneously with myositis, or develop after the muscle disease, usually within the first few months from the onset of weakness. In some patients, ILD appears in the absence of any muscle symptoms (clinically amyopathic).
        </p>
        <p>
         The lung examination may be clear on chest auscultation or reveal dry bibasilar crackles. In patients with ILD who have not yet been diagnosed with DM or PM, the presence of these disorders may be suspected in those who also have proximal muscle weakness, abnormal nailfold capillary microscopy, or unexplained rashes. However, patients may appear clinically amyopathic and rashes may be more difficult to discern in patients who are more darkly pigmented. The other signs and symptoms of PM and DM are described separately. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         The following subtypes of PM and DM warrant particular attention:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antisynthetase syndrome
         </strong>
         – A subset of patients may present with a constellation of clinical features, including myositis, ILD, nonerosive arthritis, "mechanic's hands"  (
         <a class="graphic graphic_picture graphicRef56057" href="/z/d/graphic/56057.html" rel="external">
          picture 1
         </a>
         ), “hiker’s feet,” fever, and Raynaud phenomenon, called the "antisynthetase syndrome" [
         <a href="#rid2">
          2,5,27-29
         </a>
         ]. This syndrome is supported by the presence of two or more of the aforementioned clinical features as well as autoantibodies to an aminoacyl-transfer RNA synthetase [
         <a href="#rid2">
          2,28,30-33
         </a>
         ]. (See
         <a class="local">
          'Laboratory testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">
          "Overview of and approach to the idiopathic inflammatory myopathies", section on 'Myositis-specific autoantibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amyopathic dermatomyositis
         </strong>
         – Clinically amyopathic dermatomyositis (CADM), which is characterized by the cutaneous findings of DM (eg, Gottron papules of the extensor aspects of the metacarpophalangeal (MCP) and interphalangeal (IP) joints, facial heliotrope rash, and periungual erythema) with no muscle involvement or only minimal weakness, affects 20 percent of patients with DM, but may be more common with specific autoantibodies like PL12 or melanoma differentiation-associated gene 5 (MDA-5)  (
         <a class="graphic graphic_picture graphicRef89230" href="/z/d/graphic/89230.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef63383" href="/z/d/graphic/63383.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef68649" href="/z/d/graphic/68649.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef89101" href="/z/d/graphic/89101.html" rel="external">
          picture 5
         </a>
         ) [
         <a href="#rid26">
          26,34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Skin findings in dermatomyositis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-MDA-5 antibodies
         </strong>
         – MDA-5 antibodies (previously referred to as anti-CADM-140 antibodies) can be associated with a rapidly progressive course of ILD and vasculopathy affecting the skin [
         <a href="#rid36">
          36
         </a>
         ]. Anti-MDA-5 positivity has a similar frequency among patients with CADM and classic DM [
         <a href="#rid35">
          35
         </a>
         ]. Cutaneous findings include digital and palmar papules and ulcerations  (
         <a class="graphic graphic_picture graphicRef108220" href="/z/d/graphic/108220.html" rel="external">
          picture 6
         </a>
         ), alopecia, and oral ulcers. Anti-MDA-5 disease can be present in the absence of muscle enzyme abnormalities or other autoantibodies and portends a worse prognosis and a greater likelihood of rapidly progressive ILD [
         <a href="#rid37">
          37-39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'MDA5-associated dermatomyositis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overlap syndromes
         </strong>
         – DM and PM may overlap with features of other systemic rheumatic diseases, including systemic sclerosis (SSc), systemic lupus erythematosus (SLE), mixed connective tissue disease, rheumatoid arthritis, and Sjögren’s syndrome. The myopathy associated with the other systemic rheumatic diseases can vary from clinically insignificant (with minimal muscle enzyme elevations and minimal inflammatory changes on muscle biopsy) to severe myopathy, in which DM or PM dominates the clinical picture [
         <a href="#rid40">
          40
         </a>
         ]. Patients with anti-PM-Scl and anti-Ku antibodies may have features of both PM/DM and SSc, including sclerodactyly, Raynaud phenomenon, and interstitial lung disease [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of potential dermatomyositis (DM) or polymyositis (PM) associated interstitial lung disease (ILD) usually begins when a patient with known DM or PM develops clinical or radiographic features of ILD or a patient with suspected ILD is found to have clinical features of DM or PM. The evaluation is designed to characterize the underlying rheumatic disease, to identify the type and severity of ILD, and to exclude other explanations for the patient's symptoms and signs (eg, infection, drug-induced lung toxicity, respiratory muscle weakness, myocardial dysfunction). The evaluation typically includes laboratory testing, high-resolution computed tomography (HRCT) , pulmonary function testing, and sometimes bronchoalveolar lavage. Rarely patients may need a lung biopsy. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         When ILD is suspected, initial laboratory testing should include a complete blood count and differential, hepatic and renal function tests, ferritin [
         <a href="#rid42">
          42
         </a>
         ], and, if pulmonary vascular congestion is suspected, a brain natriuretic peptide (BNP) or N-terminal-proBNP. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p>
         The main role of additional laboratory testing is to establish the diagnosis of the underlying inflammatory myopathy. For patients who do not have a confirmed diagnosis of DM or PM, we usually obtain serum muscle enzymes (eg, creatine kinase and aldolase), an antinuclear antibody (ANA) test, and an anti-Jo-1 antibody (anti-histidyl-transfer [t] RNA synthetase). If the anti-Jo-1 antibody is negative, we obtain a panel of the other myositis-specific autoantibodies, such as those directed against other aminoacyl-tRNA synthetases (eg, anti-PL-7 [anti-threonyl-tRNA synthetase], anti-PL-12 [anti-alanyl-tRNA synthetase]) and MDA-5. Of note, a negative ANA with cytoplasmic staining should raise suspicion for the presence of anti-synthetase autoantibodies since aminoacyl-tRNA synthetase enzymes reside in the cell cytoplasm. (See
         <a class="medical medical_review" href="/z/d/html/1822.html" rel="external">
          "Measurement and clinical significance of antinuclear antibodies", section on 'Cytoplasmic fine speckled'
         </a>
         .)
        </p>
        <p>
         If the ANA test is positive and an overlap syndrome is suspected, we also test for other specific autoantibodies such as anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-U1 ribonucleoprotein (RNP), anti-topoisomerase (anti-Scl-70), anti-PM-Scl, and anti-Ku. The laboratory evaluation of patients with DM or PM is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Myositis-associated autoantibodies'
         </a>
         .)
        </p>
        <p>
         The presence of individual myositis antibodies may play a role in determining the likelihood of the various disease manifestations in a given patient, although this is still an area of investigation [
         <a href="#rid43">
          43
         </a>
         ]. The presence of antisynthetase antibodies appears to be associated with a greater likelihood of ILD [
         <a href="#rid4">
          4,13,15,44-46
         </a>
         ]. As an example, in a series of 90 patients with anti-Jo-1 antibodies, the incidence of ILD approached 90 percent [
         <a href="#rid13">
          13
         </a>
         ]. In a separate series of 95 patients with antisynthetase syndrome, ILD was present in 68 percent of those with anti-Jo-1 antibodies and 90 percent of those with anti-PL-7 or anti-PL-12 antibodies [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Myositis-associated autoantibodies'
         </a>
         .)
        </p>
        <p>
         Among patients with DM or clinically amyopathic dermatomyositis (CADM), the antimelanoma differentiation-associated gene 5 (MDA-5) antibody (also known as anti-CADM-140 antibodies) may portend a more aggressive form of ILD and a worse prognosis [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         Other serum markers have been used to assess prognosis and guide disease management, but their clinical role is not established. These include HLA class II associations, serum biomarkers such as Kerbs von Lungren factor (KL-6), surfactant protein D (SP-D), ferritin, and serum chemokine levels (eg, CXCL9 and CXCL10) [
         <a href="#rid13">
          13,42,48-50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         A conventional chest radiograph is often obtained when a patient with DM or PM has a cough or dyspnea, crackles on lung exam, abnormal pulmonary function tests, or positive tests for anti-synthetase antibodies, but high-resolution computed tomography (HRCT) is preferred due to the greater sensitivity and ability to characterize the extent and pattern of interstitial changes [
         <a href="#rid32">
          32
         </a>
         ]. We obtain a HRCT to screen for ILD in all patients with antisynthetase or melanoma differentiation-associated gene 5 (MDA-5) antibodies. In addition, we typically obtain a computed tomography (CT) scan of the abdomen and pelvis if there is clinical suspicion of lung malignancy.
        </p>
        <p>
         The most common findings on chest radiography are diffuse reticular and nodular opacities, predominantly at the lung bases. Patients with fulminant disease may have patchy, "ground glass" opacities  (
         <a class="graphic graphic_diagnosticimage graphicRef83490" href="/z/d/graphic/83490.html" rel="external">
          image 1
         </a>
         ). Pleural effusions are not seen [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         HRCT is performed in the supine and prone positions if it is unclear whether opacities in dependent areas are due to gravity-induced atelectasis. Radiographic patterns include patchy ground glass opacification, basilar consolidation, septal thickening, honeycombing, and irregular linear opacities  (
         <a class="graphic graphic_diagnosticimage graphicRef83491" href="/z/d/graphic/83491.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef87914" href="/z/d/graphic/87914.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid24">
          24,51
         </a>
         ]. (See
         <a class="local">
          'Histopathology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs", section on 'Ground-glass opacification'
         </a>
         .)
        </p>
        <p>
         Sometimes the HRCT findings correlate with the underlying histopathology, and more than one pattern can be present. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ground glass opacification suggests cellular nonspecific interstitial pneumonia (NSIP)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Predominantly reticular changes suggest fibrotic NSIP or usual interstitial pneumonia (UIP)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Honeycombing suggests UIP
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patchy consolidative opacities are suggestive of organizing pneumonia (OP, previously called bronchiolitis obliterans organizing pneumonia [BOOP]) or infection
        </p>
        <p>
        </p>
        <p>
         HRCT has the advantage of being noninvasive and repeatable, permitting an assessment of response to therapy. In addition, sampling error is unlikely because the entire lung is imaged, whereas sampling error may be a problem with lung biopsy [
         <a href="#rid52">
          52-55
         </a>
         ]. Several patterns have been described that can help distinguish connective tissue disease (CTD)-associated ILD from idiopathic pulmonary fibrosis (IPF) including anterior upper lobe honeycombing, exuberant basilar honeycombing, and the straight-edge sign (fairly sharp demarcation between fibrotic changes and normal lung orthogonal to the lateral chest wall) [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs) are used to help distinguish the cause of dyspnea (eg, ILD versus respiratory muscle weakness) and to assess the severity of respiratory impairment [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p>
         In patients with ILD, PFTs typically demonstrate a restrictive pattern (low forced vital capacity [FVC] and low total lung capacity [TLC]) and a diminished diffusing capacity. Patients with early interstitial lung disease may have normal or near-normal PFTs, except for a mild decrease in oxygen saturation with six-minute walk testing.
        </p>
        <p>
         In contrast, patients with respiratory muscle weakness without ILD may have a restrictive pattern but will typically have a normal diffusing capacity and clear lung fields on HRCT. (See
         <a class="local">
          'Respiratory muscle weakness'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchoscopy with bronchoalveolar lavage can help to exclude other causes of diffuse pulmonary parenchymal opacities such as infection and alveolar hemorrhage. This is particularly important in patients who present with a worsening of pulmonary function after treatment with immunosuppressive drugs or rapid deterioration in lung function. (See
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1761582578">
         <span class="h2">
          Diagnosis of ILD in patients with DM or PM
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with known dermatomyositis (DM) or polymyositis (PM), the diagnosis of interstitial lung disease (ILD) is usually based on the combination of clinical presentation, laboratory tests, high-resolution computed tomography (HRCT) appearance, and pulmonary function test (PFT) results, as described above. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
         While HRCT is the most important test for determining the presence and type of ILD, other studies (eg, laboratory and pulmonary function tests) help to identify other causes of ILD and characterize the degree to which ILD explains the patient's symptoms. As examples for patients with DM or PM:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased peripheral blood eosinophils favor drug-induced pneumonitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A positive anti-Jo-1, or other antisynthetase antibody, increases the likelihood of ILD due to DM or PM
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PFTs showing proportionately more restriction than gas transfer abnormality suggest a greater contribution of respiratory muscle weakness than ILD to the person's dyspnea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A disproportionately low DLCO relative to lung volume may suggest pulmonary hypertension
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1939286966">
         <span class="h3">
          Determining the type of ILD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The types of ILD follow the histopathology of the various idiopathic interstitial pneumonias such as nonspecific interstitial pneumonia (most common), usual interstitial pneumonia (UIP), organizing pneumonia (OP), or acute interstitial pneumonia (AIP)  (
         <a class="graphic graphic_table graphicRef95445" href="/z/d/graphic/95445.html" rel="external">
          table 1
         </a>
         ). In general, the HRCT appearance is used to determine the type of ILD. Bronchoalveolar lavage (BAL) findings are not adequate to differentiate among the histopathologic types of ILD. A lung biopsy, while not indicated for determination of the type of ILD, may be warranted to rule out an alternative process such as a malignancy. (See
         <a class="local">
          'Histopathology'
         </a>
         above and
         <a class="local">
          'Imaging'
         </a>
         above and
         <a class="local">
          'Bronchoscopy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1939286920">
         <span class="h3">
          Atypical or rapidly progressive ILD
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the clinical course or imaging studies are atypical (eg, associated with fever, rapidly progressive, flaring during immunosuppressive therapy), bronchoscopy with BAL is typically indicated to exclude infection or drug toxicity. Acute interstitial pneumonitis can be the presenting type of ILD in patients with DM or PM but requires exclusion of other causes of diffuse alveolar damage (DAD). (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Role of bronchoalveolar lavage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1761582552">
         <span class="h2">
          Diagnosis of DM or PM in patients with ILD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, ILD may be the initial manifestation of DM or PM. In these patients, the diagnosis of underlying DM or PM is based on the presence of clinical findings such as cutaneous manifestations (eg, Gottron papules  (
         <a class="graphic graphic_picture graphicRef89230" href="/z/d/graphic/89230.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef63383" href="/z/d/graphic/63383.html" rel="external">
          picture 3
         </a>
         ), "mechanic's hands"  (
         <a class="graphic graphic_picture graphicRef56057" href="/z/d/graphic/56057.html" rel="external">
          picture 1
         </a>
         )) or “hiker’s feet”, symmetric proximal muscle weakness, nail bed capillary microscopic changes, and/or laboratory testing showing consistent serology. Muscle biopsy or thigh MRI may help to confirm the diagnosis. The diagnosis of PM or DM and the evaluation of ILD in general are discussed separately. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
         In patients with cutaneous findings suggestive of DM but without evidence of muscle weakness, the diagnosis of clinically amyopathic dermatomyositis should be considered as these patients have a high frequency of developing ILD. The diagnosis of amyopathic dermatomyositis is discussed separately.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of dermatomyositis (DM) and polymyositis (PM) as well as the immunosuppressive therapy used to treat myositis or interstitial lung disease (ILD) may cause dyspnea and cough independent of or in addition to ILD. We present several conditions below that should be considered in the initial differential diagnosis of ILD as well as in patients who develop clinical worsening or do not respond to treatment.
        </p>
        <p class="headingAnchor" id="H2371211567">
         <span class="h2">
          Cardiac causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac involvement due to DM or PM is rarely a cause of clinically apparent heart failure but should also be considered in the differential diagnosis of dyspnea. Similarly, pulmonary hypertension due to a primary vasculopathy or thromboembolic disease can present with significant dyspnea on exertion as well as a low diffusing capacity for carbon monoxide (DLCO). (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Cardiac involvement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung infection is a common and potentially lethal complication of DM and PM. Several factors may contribute to this problem [
         <a href="#rid5">
          5,28,58,59
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory muscle weakness can lead to a weak cough, atelectasis, and consequently, a predisposition to bacterial pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oropharyngeal and esophageal dysfunction may increase the risk of aspiration pneumonia [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">
          "Aspiration pneumonia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphopenia affecting both T and B cells is a frequent finding in DM, even before the initiation of immunosuppressive treatment [
         <a href="#rid61">
          61
         </a>
         ]. In one series, patients with lymphopenia had an increased frequency of pneumonia compared with those with normal cell counts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapy with high-dose glucocorticoids and other immunosuppressive agents increases the risk of opportunistic infections, including
         <em>
          Pneumocystis jirovecii
         </em>
         (previously called P. carinii), other fungi, and Nocardia [
         <a href="#rid31">
          31,61-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Features that suggest infection include a rapid worsening of respiratory symptoms and new radiographic abnormalities, a productive cough, fever, and leukocytosis. Evaluation generally includes blood cultures, sputum smear, and culture for bacteria, fungi, and mycobacteria. Induced sputum can be obtained for P. jirovecii immunofluorescence. If initial studies are unrevealing, bronchoscopy with bronchoalveolar lavage (BAL) may be needed to identify the infecting organism. Often, empiric antibiotic therapy is initiated while waiting for the results of these studies. (See
         <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">
          "Approach to the immunocompromised patient with fever and pulmonary infiltrates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2371211614">
         <span class="h2">
          Aspiration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with swallowing difficulties due to DM or PM are at increased risk for recurrent aspiration and associated lung injury. Typically, recurrent aspiration leads to focal scarring, most commonly in the lower lobes. Centrilobular fibrosis, nodules, and the "tree-in-bud" pattern are HRCT features of recurrent aspiration. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs", section on 'Centrilobular nodules'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Drug-induced pneumonitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with inflammatory myopathy, drug-induced ILD needs to be differentiated from ILD associated with the underlying myopathy.
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         and tumor necrosis factor (TNF) inhibitors have been associated with the development of drug-induced pneumonitis. One of the key diagnostic steps is assessing the response to drug withdrawal.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         – Methotrexate-induced pneumonitis can occur at any dose and at any time during a patient's use of the medication, although most cases occur within the first year. Discontinuation of the drug usually leads to rapid improvement. Methotrexate pneumonitis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following issues deserve emphasis in patients with DM and PM:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The clinical manifestations are similar to those seen with ILD or infection. One exception is that basilar predominance of opacities on chest radiograph is unusual in
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         pneumonitis and is common in ILD associated with DM and PM. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lung biopsy does not distinguish between
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         pneumonitis and an ILD caused by the underlying myositis [
         <a href="#rid62">
          62
         </a>
         ]. Infection, which is another major consideration in the differential diagnosis, can usually be excluded by bronchoalveolar lavage.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral eosinophilia, when present, suggests methotrexate-induced pneumonitis rather than ILD due to the underlying myositis. However, this finding is nonspecific and its sensitivity is unknown, particularly in patients treated with glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TNF inhibitors
         </strong>
         – TNF inhibitors are sometimes used to manage arthritis associated with DM/PM and are potential causes of drug-associated pneumonitis [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Pulmonary disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2371211669">
         <span class="h2">
          Alveolar hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rare cases of diffuse alveolar hemorrhage (DAH) complicating DM and PM have been reported [
         <a href="#rid66">
          66-68
         </a>
         ]. Possibly, these patients developed DAH as a complication of acute interstitial pneumonitis (the clinical presentation of idiopathic diffuse alveolar damage). The diagnosis of DAH is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2354824379">
         <span class="h1">
          OTHER CAUSES OF DYSPNEA IN DM AND PM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spontaneous pneumomediastinum, respiratory muscle weakness, pulmonary hypertension, and venous thromboembolism are complications of dermatomyositis (DM) and polymyositis (PM) that should be assessed in patients with DM or PM who present with dyspnea or chest discomfort.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Spontaneous pneumomediastinum
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spontaneous pneumomediastinum is a rare complication of inflammatory myositis and occurs more commonly in DM than PM  (
         <a class="graphic graphic_diagnosticimage graphicRef87913" href="/z/d/graphic/87913.html" rel="external">
          image 4
         </a>
         ) [
         <a href="#rid69">
          69,70
         </a>
         ]. Virtually all patients with DM or PM who develop a pneumomediastinum have interstitial lung disease (ILD), and the pneumomediastinum is occasionally the presenting clinical manifestation of ILD. The management of spontaneous pneumomediastinum in DM and PM is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4357.html" rel="external">
          "Interstitial lung disease in dermatomyositis and polymyositis: Treatment", section on 'Spontaneous pneumomediastinum'
         </a>
         .)
        </p>
        <p>
         Approximately one-half of patients with DM who develop a pneumomediastinum have amyopathic DM, and many have antibodies to MDA-5 [
         <a href="#rid69">
          69,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Interstitial lung disease'
         </a>
         .)
        </p>
        <p>
         It is thought that the main cause of pneumomediastinum in patients with DM and PM is architectural distortion of lung tissue due to ILD. Another possible explanation is that vasculopathic lesions within the respiratory tract may result in bronchial or alveolar wall injury and subsequent air leakage. This theory is based upon the association of pneumomediastinum with the cutaneous vasculopathic lesions that can be seen in DM and the finding of endobronchial areas of subepithelial necrosis [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The typical presentation of pneumomediastinum is the acute onset of retrosternal chest pain with neck and face swelling due to subcutaneous emphysema, which may be detectable as crepitus with palpation over areas of swelling. Some patients also complain of dyspnea [
         <a href="#rid73">
          73
         </a>
         ]. In addition, patients often have evidence of a flare of their underlying DM or PM with fever, worsening skin manifestations, Raynaud phenomenon, or weight loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – A pneumomediastinum is often visible on a plain chest radiograph as a narrow streak of air along the descending aorta, left hilum, and left cardiac shadow. This streak may extend up into the neck. When mediastinal air outlines the superior surface of the diaphragm and separates it from the heart, the finding is known as the "continuous diaphragm sign." Subcutaneous air is often seen in the neck.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A high-resolution computed tomography (HRCT) scan is usually performed to delineate the extent and characteristics of the pneumomediastinum. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Respiratory muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory muscle weakness can complicate both DM and PM and must be considered in the differential diagnosis for patients with worsening dyspnea without worsening radiographic opacities. Typical inflammatory myopathic changes have been documented in the diaphragm, intercostal muscles, and accessory muscles [
         <a href="#rid5">
          5
         </a>
         ]. The severity of impairment ranges from asymptomatic to respiratory failure.
        </p>
        <p>
         Estimates of prevalence have varied from 4 to 78 percent [
         <a href="#rid5">
          5,6,74,75
         </a>
         ]. This variation is largely dependent on the method used to assess respiratory involvement (eg, symptom report, pulmonary function tests, or transdiaphragmatic pressures) as respiratory muscle weakness may be subclinical in patients whose activity level is reduced by skeletal muscle weakness. As an example, one study evaluated diaphragm strength in 12 patients with inflammatory myopathy [
         <a href="#rid74">
          74
         </a>
         ]. Static inspiratory and expiratory pressures, as well as mouth and transdiaphragmatic pressure responses to bilateral phrenic nerve stimulation, were assessed. Diaphragm weakness was noted in 78 percent.
        </p>
        <p>
         Respiratory muscle weakness is more likely to be seen in patients with more profound skeletal muscle weakness, so the characteristics of the population studied may also affect the reported prevalence.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Symptomatic patients may complain of dyspnea, orthopnea, insomnia, daytime sleepiness, and impaired cognition. Symptoms and signs of bulbar muscle weakness (eg, difficulty swallowing, dysarthria, nasal speech) may also be present. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypercapnic respiratory failure caused by diaphragmatic muscle weakness has been reported in PM and DM, rarely as the presenting manifestation [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary function testing
         </strong>
         – Objective physiologic testing is necessary to confirm and monitor respiratory muscle weakness and usually includes measurement of forced vital capacity (FVC) sitting and supine, maximum voluntary ventilation (MVV), maximal inspiratory pressure (MIP), maximum expiratory pressure (MEP), and gas transfer. A decrease in FVC of &gt;10 percent from sitting to supine suggests respiratory muscle weakness. The interpretation of these tests is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When respiratory muscle weakness is identified, the adequacy of oxygenation should be assessed when the patient is at rest, during exertion, and during sleep.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The arterial carbon dioxide tension (PaCO
         <sub>
          2
         </sub>
         ) should be assessed in the following situations [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complaint of daytime sleepiness
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maximal inspiratory and expiratory pressures are less than 30 percent of normal
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         FVC is less than 55 percent of predicted
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The treatment of respiratory muscle weakness in DM and PM follows the regimen used for skeletal myositis and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Supportive care for patients with respiratory muscle weakness includes supplemental oxygen, noninvasive ventilation (NIV), nocturnal BPAP, and cough assistance. The decisions about when and where to initiate NIV and cough assistance measures are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5124.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5118.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Practical aspects of initiation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2246138271">
         <span class="h3">
          Pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension (group 3) can develop as a consequence of severe ILD in patients with DM or PM [
         <a href="#rid76">
          76-79
         </a>
         ]. In a series of 203 consecutive patients with antisynthetase syndrome, pulmonary hypertension was suggested by transthoracic echocardiogram in 47 and confirmed in 16 of the 21 who underwent right heart catheterization [
         <a href="#rid76">
          76
         </a>
         ]. ILD was present in all of the confirmed cases, although the severity of pulmonary hypertension was thought to suggest concomitant pulmonary vasculopathy in 13 patients and thromboembolic disease in one.
        </p>
        <p class="headingAnchor" id="H56703487">
         <span class="h2">
          Thromboembolic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of venous thromboembolism (VTE) is increased among patients with DM or PM [
         <a href="#rid80">
          80,81
         </a>
         ]. The evaluation and diagnosis of VTE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H866726242">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114586.html" rel="external">
          "Society guideline links: Dermatomyositis and polymyositis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23396495">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/578.html" rel="external">
          "Patient education: Polymyositis, dermatomyositis, and other forms of idiopathic inflammatory myopathy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ILD occurs in approximately 60 to 80 percent of patients with dermatomyositis (DM) or polymyositis (PM); it may be chronic and slowly progressive or acute and rapidly progressive. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several histologic patterns of ILD are associated with DM and PM: nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP, also known as bronchiolitis obliterans with organizing pneumonia [BOOP]), and acute interstitial pneumonia (AIP, also known as diffuse alveolar damage [DAD]). (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with DM or PM-associated ILD typically complain of dyspnea and a nonproductive cough, although some patients are asymptomatic, and ILD is suspected because of an abnormal lung exam or an abnormal chest radiograph. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain subtypes of PM and DM warrant particular attention as they are more likely to manifest ILD or to have more severe disease. These subtypes include patients with the antisynthetase syndrome (associated with "mechanics hands"), antimelanoma differentiation-associated gene 5 (MDA-5) antibodies, which are associated with distinct cutaneous findings (eg, palmar papules and ulcerating lesions  (
         <a class="graphic graphic_picture graphicRef108220" href="/z/d/graphic/108220.html" rel="external">
          picture 6
         </a>
         )), and the overlap syndromes associated with features of other systemic rheumatic diseases in addition to DM or PM. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial laboratory testing typically includes a complete blood count and differential, hepatic and renal function tests, and a brain natriuretic peptide (BNP) or N-terminal-proBNP. If the diagnosis of DM or PM has not been confirmed, we usually obtain serum muscle enzymes (eg, creatine kinase and aldolase), an antinuclear antibody test, and an anti-Jo-1 antibody. Additional testing (eg, other antisynthetase antibodies, anti-antimelanoma differentiation-associated gene 5 [MDA-5] antibodies, testing for an overlap syndrome) is based on the clinical examination and results of the initial tests. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-resolution computed tomography (HRCT) is the preferred imaging test due to its greater sensitivity and ability to characterize the extent and pattern of interstitial changes. Radiographic patterns reflect the underlying pathology and include ground glass opacification, peripheral or basal consolidation, septal thickening, honeycombing, and irregular linear opacities, with patchy ground glass opacities and septal thickening being most common  (
         <a class="graphic graphic_diagnosticimage graphicRef83491" href="/z/d/graphic/83491.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of ILD in patients with known DM and PM can usually be established based on the clinical presentation, chest imaging studies (ie, HRCT), and pulmonary function tests. Lung biopsy is usually not necessary. However, when the clinical course or imaging studies are atypical (eg, associated with fever, rapidly progressive, developing during immunosuppressive therapy), bronchoscopy with bronchoalveolar lavage (BAL) is typically performed to exclude infection or drug toxicity. If the diagnosis remains in doubt, a lung biopsy may be indicated. (See
         <a class="local">
          'Diagnosis of ILD in patients with DM or PM'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ILD may be the initial manifestation of DM or PM. In these patients, the diagnosis of underlying DM or PM is based on the presence of clinical findings such as cutaneous manifestations (eg, Gottron papules  (
         <a class="graphic graphic_picture graphicRef63383" href="/z/d/graphic/63383.html" rel="external">
          picture 3
         </a>
         ), "mechanic's hands"  (
         <a class="graphic graphic_picture graphicRef56057" href="/z/d/graphic/56057.html" rel="external">
          picture 1
         </a>
         )), symmetric proximal muscle weakness, nail bed capillary microscopic changes, and/or laboratory testing. Muscle biopsy or thigh MRI may be needed to confirm the diagnosis. (See
         <a class="local">
          'Diagnosis of DM or PM in patients with ILD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis of ILD in patients with DM or PM includes heart failure, infection, recurrent aspiration, drug-induced pneumonitis), pulmonary hypertension, and, rarely, alveolar hemorrhage. Any drug suspected of causing pneumonitis should be discontinued and the response to drug withdrawal assessed. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional etiologies of deteriorating pulmonary status that should be assessed in patients with DM or PM include spontaneous pneumomediastinum, respiratory muscle weakness, pulmonary hypertension, and venous thromboembolism. (See
         <a class="local">
          'Other causes of dyspnea in DM and PM'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of ILD in patients with DM or PM is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4357.html" rel="external">
          "Interstitial lung disease in dermatomyositis and polymyositis: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2367548179">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Marc Miller, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010; 138:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984; 14:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 1974; 65:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings. Arch Intern Med 1981; 141:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nambu Y, Mouri M, Toga H, et al. Gender and underlying diseases affect the frequency of the concurrence of adult polymyositis/dermatomyositis and interstitial pneumonia. Chest 1994; 106:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus 2015; 4:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson C, Schiffenbauer AI, Miller FW, et al. Human Leukocyte Antigen Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy. Am J Respir Crit Care Med 2023; 207:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothwell S, Chinoy H, Lamb JA. Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis. Curr Opin Rheumatol 2019; 31:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. J Rheumatol 2018; 45:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011; 37:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Matthay RA, Sahn SA, et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine (Baltimore) 1976; 55:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox JT, Gullotti DM, Mecoli CA, et al. "Hiker's feet": a novel cutaneous finding in the inflammatory myopathies. Clin Rheumatol 2017; 36:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lakhanpal S, Lie JT, Conn DL, Martin WJ 2nd. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1987; 46:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padley SP, Hansell DM, Flower CD, Jennings P. Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin Radiol 1991; 44:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135:1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gil B, Merav L, Pnina L, Chagai G. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol 2016; 35:2125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghadam-Kia S, Oddis CV, Sato S, et al. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. J Rheumatol 2017; 44:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nandy A, Gaïni S, Sore P. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis. Scand J Rheumatol 2018; 47:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 2013; 65:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceribelli A, Fredi M, Taraborelli M, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014; 32:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 2014; 5:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomonaga M, Sakamoto N, Ishimatsu Y, et al. Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Lung 2015; 193:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012; 11:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012; 91:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumánovics G, Minier T, Radics J, et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008; 26:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008; 35:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AU, du Bois RM. Bronchiolitis in association with connective tissue disorders. Clin Chest Med 1993; 14:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997; 169:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akira M, Hara H, Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999; 210:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003; 123:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung JH, Cox CW, Montner SM, et al. CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. AJR Am J Roentgenol 2018; 210:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morganroth PA, Kreider ME, Okawa J, et al. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 2010; 146:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Astudillo LM, Carreiro M, Sailler L, et al. Hypercapnic coma due to diaphragmatic involvement in a patient with dermatomyositis. Clin Exp Rheumatol 2001; 19:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007; 82:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguier M, Fouéré S, de la Salmonière P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 2003; 82:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sostman HD, Matthay RA, Putman CE, Smith GJ. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976; 55:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Do-Pham G, Pagès C, Picard C, et al. A first case report of a patient with paraneoplastic dermatomyositis developing diffuse alveolar haemorrhage. Br J Dermatol 2010; 163:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Sutarik JM, Nick JA, et al. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis. Am J Respir Crit Care Med 1995; 151:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato K, Morozumi S, Takeuchi Y, et al. [Case of dermatomyositis with anti-CADM-140 antibody and alveolar hemorrhage]. Rinsho Shinkeigaku 2014; 54:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Goff B, Chérin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamaguchi K, Yamaguchi A, Itai M, et al. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 2019; 38:3443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma X, Chen Z, Hu W, et al. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 2016; 35:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000; 59:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caceres M, Ali SZ, Braud R, et al. Spontaneous pneumomediastinum: a comparative study and review of the literature. Ann Thorac Surg 2008; 86:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 2005; 15:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005; 14:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013; 42:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatterjee S, Farver C. Severe pulmonary hypertension in Anti-Jo-1 syndrome. Arthritis Care Res (Hoboken) 2010; 62:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handa T, Nagai S, Kawabata D, et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med 2005; 44:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016; 352:h6819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 2016; 75:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung WS, Lin CL, Sung FC, et al. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res 2014; 134:622.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4304 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522835" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Interstitial lung disease in polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1659647" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438901" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21138882" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6385255" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pulmonary disease in polymyositis/dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/327194" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4819244" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Interstitial pneumonitis in association with polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7247586" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3515559" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4093921" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Dermatopolymyositis and other connective tissue diseases: a review of 105 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7988241" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Gender and underlying diseases affect the frequency of the concurrence of adult polymyositis/dermatomyositis and interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26101728" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19565490" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11298544" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11673206" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Polymyositis-dermatomyositis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36269757" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Human Leukocyte Antigen Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31415030" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2310101" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12952255" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20190466" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29606668" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21390438" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Myositis-related interstitial lung disease and antisynthetase syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17557770" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14962966" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19565506" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1246203" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3187543" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28389987" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : "Hiker's feet": a novel cutaneous finding in the inflammatory myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19581351" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3813671" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1959296" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19225060" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25846833" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28089977" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29043891" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23908005" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25151986" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414240" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25923553" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Inflammatory muscle diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26000158" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Myositis autoantibodies and clinical phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385617" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25394672" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22326685" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22732951" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23203765" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23436757" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10813282" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16507114" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18578962" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18085731" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8313670" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Bronchiolitis in association with connective tissue disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207505" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10207411" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12684299" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29140119" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20644033" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6412385" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11491505" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Hypercapnic coma due to diaphragmatic involvement in a patient with dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17418072" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12640184" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/957997" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Methotrexate-induced pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818648" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Opportunistic infections in polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8823690" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21277618" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20394626" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A first case report of a patient with paraneoplastic dermatomyositis developing diffuse alveolar haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7767555" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24943077" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : [Case of dermatomyositis with anti-CADM-140 antibody and alveolar hemorrhage].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19116970" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31420814" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26149923" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10784520" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18721592" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Spontaneous pneumomediastinum: a comparative study and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15639118" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16130510" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23397301" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20391490" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Severe pulmonary hypertension in Anti-Jo-1 syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15897644" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26912511" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Management of interstitial lung disease associated with connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25193998" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25034321" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
